Nuvectis Pharma (NVCT) Payables (2021 - 2026)
Nuvectis Pharma (NVCT) posted Payables of $4.7 million for Q1 2026, down 25.17% sequentially from $6.3 million in Q4 2025, and up 56.92% YoY from $3.0 million in Q1 2025.
Nuvectis Pharma (NVCT) Payables (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Payables for 6 years, with the latest figure at $4.7 million in Q1 2026.
- Quarterly Payables rose 56.92% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (up 56.92% YoY) and the FY2025 annual result came in at $6.3 million, up 151.16% from the prior year.
- Payables retreated to $4.7 million in Q1 2026 per NVCT's latest filing, from $6.3 million in the prior quarter.
- Over five years, Payables peaked at $6.4 million in Q3 2025 and troughed at $1.3 million in Q1 2022.
- A 5-year average of $3.0 million and a median of $2.5 million in 2024 frame the typical range for Payables.
- The sharpest annual moves came in 2024 and 2025: Payables tumbled 35.25% in 2024, then surged 184.79% in 2025.
- Over 5 years, Payables stood at $2.9 million in 2022, then slipped by 4.78% to $2.8 million in 2023, then declined by 9.85% to $2.5 million in 2024, then jumped by 151.16% to $6.3 million in 2025, then decreased by 25.17% to $4.7 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $4.7 million, $6.3 million, and $6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | 5.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.18 Mn |
| Mar 31, 2026 | 4.70 Mn |
| Dec 31, 2025 | 6.27 Mn |
| Sep 30, 2025 | 6.44 Mn |
| Jun 30, 2025 | 4.98 Mn |
| Mar 31, 2025 | 2.99 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Sep 30, 2024 | 2.26 Mn |
| Jun 30, 2024 | 1.85 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Dec 31, 2023 | 2.77 Mn |
| Sep 30, 2023 | 3.49 Mn |
| Jun 30, 2023 | 1.80 Mn |
| Mar 31, 2023 | 2.10 Mn |
| Dec 31, 2022 | 2.91 Mn |
| Sep 30, 2022 | 2.25 Mn |
| Jun 30, 2022 | 1.43 Mn |
| Mar 31, 2022 | 1.35 Mn |
| Dec 31, 2021 | 1.06 Mn |